治疗慢性阻塞性肺疾病新药-罗氟司特

Roflumilast is a phosphodiesterase IV inhibitor that was first approved by the EMA in 2010 as an add-on therapy to the treatment of bronchiectasis for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) in adult patients with chronic bronchitis who have a history of frequent exacerbations. In Europe, there are multiple trade names, including Daxas, Libertek and Daliresp, and were first launched in Germany in 2010 and soon thereafter in the UK. After supplementing relevant information and data analysis as required by the FDA, roflumilast was approved by the FDA in March 2011 and launched in the United States in June of that year.

Roflumilast can inhibit the decomposition of cyclic nucleotide (cAMP) and promote its accumulation in cells, thereby activating protein kinase A and regulating immune and inflammatory responses. Roflumilast can reduce the activity of airway inflammatory cells, inhibit the production of pro-inflammatory factors, and block the transmission of pro-inflammatory response information. Roflumilast can inhibit the expression of intracellular adhesion molecules and CD11b, inhibit the release of TNF-α and chemokines by lung macrophages, and reduce local inflammatory reactions. Roflumilast can affect the expression of TGF-β1, fibronectin, connective tissue growth factor collagen 1 IL6 and other substances in airway smooth muscle cells, inhibiting airway remodeling. Roflumilast can inhibit excessive airway mucus secretion, reduce airway mucus protein levels, and promote ciliary swinging.

At present, roflumilast is not yet available in China, so domestic patients cannot purchase the drug in China for the time being. If patients need this drug, they may wish to seek help from the domestic reliable overseas medical service organization Medical Companion Travel. This is an institution with formal drug purchase channels. Overseas drugs are directly mailed and delivered directly to patients. It is convenient and safe. It is currently the best channel for patients to purchase regular roflumilast. You are welcome to consult Medical Companion Travel at any time to answer your questions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.